Ask AI
ProCE Banner Activity

Immune Checkpoint Inhibitor–Based Therapy for Early-Stage Lung Cancer: Medical Oncology Perspective

Slideset Download

Download this slideset to review key data on the use of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy for resectable early-stage NSCLC.

Released: August 26, 2021

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Genentech, a member of the Roche Group

Faculty Disclosure

Primary Author

Patrick Forde, MD, PhD

Medical Oncologist & Professor, Trinity College Dublin, Ireland
Professor, Johns Hopkins
Baltimore, Maryland

Patrick Forde, MD, PhD: researcher: AstraZeneca, BioNTech, Bristol Myers Squibb, Regeneron, Summit; consultant/advisor/speaker: Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Flame, Fosun, F-Star, G1, Genentech, Iteos, Janssen, Novartis, Regeneron, Sanofi.